162 related articles for article (PubMed ID: 24791699)
1. Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells.
Ma N; Xiao H; Marrero B; Xing C; Wang X; Zheng M; Han G; Chen G; Hou C; Shen B; Li Y; Wang R; Jiang Z
Cell Immunol; 2014; 289(1-2):140-4. PubMed ID: 24791699
[TBL] [Abstract][Full Text] [Related]
2. BAFF suppresses IL-15 expression in B cells.
Ma N; Xing C; Xiao H; He Y; Han G; Chen G; Hou C; Marrero B; Wang Y; Zhang S; Shen B; Li Y; Wang R
J Immunol; 2014 May; 192(9):4192-201. PubMed ID: 24670802
[TBL] [Abstract][Full Text] [Related]
3. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
[TBL] [Abstract][Full Text] [Related]
4. TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression.
Arkatkar T; Jacobs HM; Du SW; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Kidney Int; 2018 Oct; 94(4):728-740. PubMed ID: 29907458
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
6. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
7. Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice.
Wang X; Xiao H; Wei Y; Liu X; Han G; Chen G; Hou C; Shen B; Li Y; Wang R
Cent Eur J Immunol; 2015; 40(2):142-8. PubMed ID: 26557026
[TBL] [Abstract][Full Text] [Related]
8. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
Jacob CO; Yu N; Guo S; Jacob N; Quinn WJ; Sindhava V; Cancro MP; Goilav B; Putterman C; Migone TS; Stohl W
Arthritis Rheum; 2013 Apr; 65(4):1043-54. PubMed ID: 23334904
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus.
Ramanujam M; Wang X; Huang W; Schiffer L; Grimaldi C; Akkerman A; Diamond B; Madaio MP; Davidson A
J Immunol; 2004 Sep; 173(5):3524-34. PubMed ID: 15322217
[TBL] [Abstract][Full Text] [Related]
10. Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.
Wang W; Rangel-Moreno J; Owen T; Barnard J; Nevarez S; Ichikawa HT; Anolik JH
J Immunol; 2014 Apr; 192(7):3011-20. PubMed ID: 24574498
[TBL] [Abstract][Full Text] [Related]
11. TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice.
Jacobs HM; Arkatkar T; Du SW; Scharping NE; Woods J; Li QZ; Hudkins KL; Alpers CE; Rawlings DJ; Jackson SW
Eur J Immunol; 2021 Sep; 51(9):2225-2236. PubMed ID: 34146342
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.
Liang B; Gardner DB; Griswold DE; Bugelski PJ; Song XY
Immunology; 2006 Nov; 119(3):296-305. PubMed ID: 17067309
[TBL] [Abstract][Full Text] [Related]
13. Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.
Jacob CO; Yu N; Sindhava V; Cancro MP; Pawar RD; Putterman C; Stohl W
Arthritis Rheumatol; 2015 Sep; 67(9):2523-35. PubMed ID: 25989238
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.
Jacobi AM; Huang W; Wang T; Freimuth W; Sanz I; Furie R; Mackay M; Aranow C; Diamond B; Davidson A
Arthritis Rheum; 2010 Jan; 62(1):201-10. PubMed ID: 20039404
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.
Wang X; Huang W; Mihara M; Sinha J; Davidson A
J Immunol; 2002 Feb; 168(4):2046-53. PubMed ID: 11823542
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid.
Alarcón-Riquelme ME; Möller G; Fernández C
Clin Immunol Immunopathol; 1992 Mar; 62(3):264-9. PubMed ID: 1541052
[TBL] [Abstract][Full Text] [Related]
17. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
18. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus.
Wang X; Huang W; Schiffer LE; Mihara M; Akkerman A; Hiromatsu K; Davidson A
Arthritis Rheum; 2003 Feb; 48(2):495-506. PubMed ID: 12571860
[TBL] [Abstract][Full Text] [Related]
19. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
20. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.
Tchorbanov AI; Voynova EN; Mihaylova NM; Todorov TA; Nikolova M; Yomtova VM; Chiang BL; Vassilev TL
Eur J Immunol; 2007 Dec; 37(12):3587-96. PubMed ID: 18034421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
